AnaBios Introduces High-Quality Human Primary Liver Cells for Preclinical Drug Discovery
24 mars 2022 08h00 HE
|
AnaBios
SAN DIEGO, March 24, 2022 (GLOBE NEWSWIRE) -- Today, AnaBios announced it will start providing high-quality human primary liver cells to pharmaceutical, biotech and academic laboratories to further...
2022 Worldwide Market for Cultured Meat Report - Featuring 3D Bio-Tissues, Agulos Biotech and Aleph Farms Among Others
02 févr. 2022 04h53 HE
|
Research and Markets
Dublin, Feb. 02, 2022 (GLOBE NEWSWIRE) -- The "Global Market for Cultured Meat - Market Size, Trends, Competitors, and Forecasts (2022)" report has been added to ResearchAndMarkets.com's offering. ...
Global Liver Institute Leads Second Annual Rare Liver Diseases Month
01 févr. 2022 10h41 HE
|
Global Liver Institute
Washington, DC, USA, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Global Liver Institute (GLI), a patient-led liver health nonprofit operating globally, is proud to announce today the launch of its second...
Global Liver Institute and TriSalus Life Sciences Partner To Launch “Liver Central,” a New Resource Hub for Liver Cancer Researchers, Clinicians and Patients
06 janv. 2022 10h04 HE
|
Global Liver Institute
Sterling, Jan. 06, 2022 (GLOBE NEWSWIRE) -- The Global Liver Institute (GLI), the only patient-led liver health nonprofit operating internationally, in partnership with TriSalus Life Sciences®, an...
Global Liver Institute Recognized with Two Advocacy Awards for Enduring Contributions and Sustained Service
19 nov. 2021 11h58 HE
|
Global Liver Institute
Washington, DC, USA, Nov. 19, 2021 (GLOBE NEWSWIRE) -- (Washington, DC, Friday, November 19, 2021) — Global Liver Institute (GLI), the only patient-led liver health nonprofit operating...
« The New England Journal of Medicine » publie les résultats de l’étude clinique de Phase IIb NATIVE d’Inventiva avec lanifibranor dans la NASH
20 oct. 2021 17h07 HE
|
INVENTIVA
Dans l’étude clinique de Phase IIb, lanifibranor avait atteint les critères d’évaluation principaux et secondaires, incluant la résolution de la NASH sans aggravation de la fibrose et l'amélioration...
The New England Journal of Medicine publishes the results of the NATIVE Phase IIb clinical trial with lanifibranor in NASH
20 oct. 2021 17h07 HE
|
INVENTIVA
In the Phase IIb NATIVE, lanifibranor met both the primary and key secondary endpoints, including NASH resolution with no worsening of fibrosis and improvement of liver fibrosis with no worsening of...
Inventiva annonce la présentation de cinq abstracts scientifiques lors du The Liver Meeting™ 2021 organisé par l’AASLD
18 oct. 2021 16h00 HE
|
INVENTIVA
Quatre présentations par poster confirment les effets bénéfiques de lanifibranor sur des composants clés de la NASH faisant suite à des analyses supplémentaires réalisées sur les résultats de l'étude...
Inventiva announces the presentation of five scientific abstracts at the AASLD The Liver Meeting™ 2021
18 oct. 2021 16h00 HE
|
INVENTIVA
Four poster presentations add to the evidence of the beneficial effects of lanifibranor therapy on key components of NASH, following further sub-analyses of Inventiva’s NATIVE Phase IIb clinical trial...
Global Organ Care System for Liver Market Predicted to Garner a Revenue of $42.7 Million at a CAGR of 9.3% during the Forecast Period, 2019-2026 COVID-19 Disaster - Exclusive Report by Research Dive
21 sept. 2021 09h35 HE
|
Research Dive
New York, USA, Sept. 21, 2021 (GLOBE NEWSWIRE) -- According to a recent report by Research Dive, the global organ care system for liver market is forecasted to reach $42.7 million by the end of...